secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2026-06-22T11:11:41+00:00
Accession:  0001193125-26-276694
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand proposes $550M convertible notes due 2031; amends credit facility covenants
--------------------------------------------------------------------------------

- Proposes $550M aggregate principal of convertible senior notes due 2031; additional $82.5M option granted to initial purchasers.
- Net proceeds to fund convertible note hedge costs, up to $75M share repurchase, and general corporate purposes including Xoma acquisition.
- Enters convertible note hedge and warrant transactions to reduce potential dilution from note conversion.
- Fourth Amendment to credit agreement sets minimum EBITDA at $100M for periods ending June 30, 2026 through March 31, 2027, then $150M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000119312526276694/0001193125-26-276694-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000119312526276694/d41408d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-276694

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer